The core problem, according to the authors, is that assessment of PIH severity currently depends exclusively on visual inspection and patient self-reporting. Both approaches are vulnerable to perception bias, and both can be strongly influenced by ambient lighting conditions, which vary enormously between examination rooms, clinics, and research settings. Unlike many other dermatologic disorders, PIH lacks a standardized clinical scale for assessment, and this absence creates inconsistencies in evaluating disease progression and treatment outcomes. Two clinicians looking at the same lesion may disagree on whether it has lightened, and a patient’s own sense of improvement may not align with what a physician observes. In clinical trials, this subjectivity can blur the signal that researchers are trying to detect, making it harder to demonstrate whether an experimental therapy actually works.

The diagnostic challenges associated with pigmentary disorders more broadly highlight the limitations of subjective visual assessment and support the development of standardized, quantitative methods. Standardized quantitative measurements for PIH would ensure accurate, reproducible, and unbiased assessments regardless of external influences such as lighting or observer expectation. The authors emphasize that objective assessment is particularly important for monitoring therapeutic response over time and for improving the consistency of outcomes in clinical trials evaluating PIH interventions. There is also a counseling dimension: measurable, objective evidence of pigmentary improvement would allow clinicians to give patients concrete feedback, enabling direct and accurate measurement of patient outcomes rather than vague reassurances that a lesion is fading.

Other objective tools do exist. Reflectance confocal microscopy can image pigment at the cellular level, dermoscopy magnifies surface structures, and spectrophotometry can decompose reflected light into its spectral components. Each of these techniques provides valuable pigmentary or structural information. Yet the research letter argues that colorimetry is especially well suited for PIH assessment because it is noninvasive, practical, reproducible, and capable of providing quantitative measurements of pigmentation that can be easily tracked longitudinally. In other words, it occupies a practical middle ground: more objective than the eye, but far simpler and cheaper to deploy in routine practice than advanced imaging platforms.

Colorimetry works by measuring the intensity of light reflectance from the skin, converting what the eye perceives as color into objective numerical data on pigmentation and erythema. The technique has a long pedigree in skin color metrics. It expresses color in three values, corresponding to lightness on a white-to-black axis, a red-to-green axis, and a yellow-to-blue axis, within a three-dimensional color space. This tristimulus representation allows any skin color to be plotted as a point in a defined coordinate system, so that changes over time can be expressed as precise numerical shifts rather than subjective impressions. A fading brown patch, for example, would show a measurable increase in the lightness value, and the magnitude of that shift can be compared across patients, visits, and studies.

The track record of colorimetry in pigmentary research is substantial. It has been used to measure pigmentary involvement in PIH treatment studies, including a landmark trial of topical tretinoin for hyperpigmented lesions caused by cutaneous inflammation in Black patients, published in the New England Journal of Medicine in the 1990s. It has also featured in PIH models that assessed histologic, clinical, spectroscopic, and colorimetric traits in parallel, allowing researchers to correlate what the device measured with what was happening in the skin itself. Beyond PIH, colorimetry has been applied to broader pigmentary disorders, including melasma and vitiligo, where it has been used to track skin lightening and repigmentation over time. The authors argue that this history of successful application in related conditions further supports its utility as a standardized tool for monitoring pigmentary changes longitudinally in PIH specifically.

The vision implicit in the research letter is a clinical scale for PIH anchored in colorimetric values rather than photographic comparisons or ordinal grading by eye. Such a scale would transform how the severity of the condition is communicated and studied. Instead of describing a lesion as mild, moderate, or severe, clinicians could report a lightness value and its deviation from the patient’s baseline skin color, with defined thresholds separating grades of severity. Treatment response could be expressed as the rate of change in those values, giving trials a continuous, statistically powerful endpoint. Because the measurements are numerical, they could be pooled across centers and populations, something that subjective grading has never reliably achieved.

The authors are candid about the hurdles that stand between this vision and routine practice. The cost and availability of colorimetric instruments remain barriers, particularly in resource-limited settings, and operator training is required to obtain consistent readings. Integrating these measurements into established clinical workflows is another practical challenge, since clinic visits are already time-pressured. More fundamentally, colorimetric measurements may be influenced by baseline pigmentation, melanin content, and device-specific calibration, all of which can affect measurement accuracy across varying skin tones and ethnic populations. A device calibrated against one reference population may not perform identically on another, and the very patients who stand to benefit most from objective PIH assessment, those with darker skin types, are the ones for whom calibration issues could be most consequential.

For these reasons, the research letter calls for future studies to validate colorimetric measurements in diverse populations and to assess whether reference ranges are needed. Establishing normative values across the full spectrum of skin tones would be a prerequisite for any scale that aspires to universal use. The authors, a team of dermatology researchers and clinicians affiliated with Texas Tech University Health Sciences Center, Texas Tech Health Sciences Center El Paso, and the Westlake Dermatology Clinical Research Center, report no funding source and no conflicts of interest, and the study received an ethics exemption as a research letter that generated no new datasets.

The significance of the argument extends beyond a single condition. PIH is a frequent sequela of acne, eczema, infections, cosmetic procedures, and injuries, and it disproportionately affects people of color, a population that has historically been underrepresented in dermatologic research. A validated, objective scale would not only improve individual patient care but also raise the methodological quality of the trials that test new treatments, potentially accelerating the development of therapies for a condition that currently has no standardized way to measure its own severity. Colorimetry is not a new technology, but applying it systematically to PIH could be the step that turns a stubbornly subjective clinical problem into a quantitatively tractable one. As the authors suggest, the tools already exist; what is needed now is the validation work to build a scale that clinicians and regulators can trust.

Subject of Research: Using colorimetry to develop an objective clinical scale for post-inflammatory hyperpigmentation

Article Title: The potential of colorimetry in developing a clinical scale for post-inflammatory hyperpigmentation

Article References: Verma, K. K., Goldstein, D. R., Friedmann, D. P., & Tarbox, M. B. (2026). The potential of colorimetry in developing a clinical scale for post-inflammatory hyperpigmentation. Archives of Dermatological Research, 318(1), Article 403. https://doi.org/10.1007/s00403-026-04935-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04935-7

Keywords: post-inflammatory hyperpigmentation, colorimetry, dermatology, skin pigmentation, clinical scale, melanin, spectrophotometry, Fitzpatrick skin type, treatment outcome, quantitative assessment, melasma, vitiligo

The study, whose full title is “Transcriptomic analyses link changes in gene expression to defects in pigment cell differentiation and eye morphogenesis in a zebrafish model for Oculocutaneous Albinism Type 2,” was published on 7 August 2026 and carries the DOI 10.1016/j.ydbio.2026.07.011. In it, Cooper and her colleagues examined zebrafish embryos carrying a mutation in the fish version of the OCA2 gene and tracked how pigment cells and the eyes formed compared with embryos lacking the mutation. What they found was not simply a loss of color. Instead, the mutation produced unexpected changes in the number and location of specialized pigment cells, altered the timing of key events in eye formation, and shifted the activity of dozens of other genes across the developing embryo.

OCA2 is best known as one of the principal genes implicated in oculocutaneous albinism, a condition that affects an estimated one in 17,000 people worldwide, though prevalence varies considerably among populations. The gene encodes a protein involved in the regulation of melanin production, and disruptions to it reduce or eliminate pigmentation in the skin, hair and eyes. For decades, the clinical features of albinism have been understood primarily through the lens of pigment deficiency. Yet the defining burden of the condition for many patients is not the loss of color itself but the vision problems that accompany it, including reduced visual acuity and involuntary eye movements known as nystagmus, which can create lifelong challenges with everyday activities such as reading and driving.

It is precisely this gap between pigment biology and visual pathology that the WSU team set out to explore. “We’re interested in understanding processes that you wouldn’t necessarily expect to depend on melanin, but it turns out they do,” said Cooper, the study’s corresponding author. “It’s another surprising mechanism that cells are using to develop correctly.” Her comment captures the central surprise of the work: a gene conventionally cast as a pigment regulator appears to participate in developmental programs that govern how tissues, including the eye, take shape.

The choice of zebrafish as the experimental platform was no accident. Like humans, zebrafish are vertebrates and deploy many of the same genes to produce pigment cells, making them a genetically relevant model for studying pigmentation disorders. Their embryos are transparent and develop rapidly outside the body, allowing researchers to observe, in real time and under the microscope, biological changes that would be extraordinarily difficult to capture in mammalian or human development. Cooper has worked with the fish for more than twenty years, and the species has an established track record in studies ranging from heart development to neurological disorders and cancer.

For the new study, the researchers examined embryos carrying the OCA2 mutation and followed two threads of investigation in parallel. The first was observational: they tracked how pigment cells and the eyes developed in the mutant embryos. The second was molecular: they compared gene activity, or transcriptomic profiles, between embryos with the mutation and embryos without it, using the differences to identify which genetic programs were disrupted. This combination of direct developmental observation with genome-wide expression analysis is what allowed the team to connect visible defects to underlying changes in gene regulation.

One of the most striking observations involved iridophores, a class of reflective pigment cells found in fish and amphibians that give zebrafish their characteristic silvery and iridescent stripes. The mutant embryos showed unexpected differences in both the number and the location of these cells. Humans do not possess iridophores, but the cells arise from the neural crest, a transient embryonic tissue that in humans also gives rise to a wide array of cell types, including parts of the peripheral nervous system, facial structures and other pigment cells. That shared developmental origin makes iridophores a valuable window into how a mutation in a pigment-related gene can ripple outward and affect cell differentiation more generally, even in lineages that do not exist in our own species.

The developing eyes told a parallel story of disruption. In the mutant embryos, a temporary opening in the embryonic eye, a normal feature of early development that must close for the eye to form properly, took longer than usual to seal. Meanwhile, cells in the retina developed and organized differently than in their unaffected counterparts. These defects in eye morphogenesis are particularly intriguing given that structural abnormalities of the eye, including defects in the way retinal cells are organized and routed to the brain, are central to the visual impairment seen in people with albinism. The zebrafish data suggest that OCA2 may be connected to these processes in ways that go beyond simply supplying melanin to the developing tissue.

The transcriptomic comparison reinforced that impression. When the researchers contrasted gene activity in embryos with and without the mutation, they identified changes in dozens of genes, including many that help cells determine what they will become and that guide the formation of the eyes and other tissues. In other words, perturbing OCA2 did not merely silence a pigment pathway; it appeared to reconfigure regulatory networks involved in cell fate decisions and organ formation. The authors’ use of the term “transcriptomic analyses” in the article title reflects this genome-scale approach, which treats the mutation’s effects as a system-wide shift in gene expression rather than a single broken link in a linear pathway.

The researchers are careful to note that the findings cannot yet be assumed to apply directly to people. Zebrafish biology, while broadly conserved with ours, differs in important respects, and iridophores in particular have no direct human equivalent. Cooper said the next steps will be to determine where, when and why the altered gene activity occurs, and then to look for similar effects in mammals and, eventually, in human cells. Establishing that the same developmental programs are affected in human embryos or patient-derived cells would be a critical step toward translating the zebrafish observations into clinically relevant knowledge.

If those connections hold, the implications could be significant. By revealing more about how albinism-related mutations affect development, the research could eventually help identify possible treatment targets for the vision complications associated with the condition, which currently have limited therapeutic options. A clearer understanding of how cells normally develop and organize themselves, and of what happens when that process goes awry, could also inform research into other diseases, Cooper noted, including cancer, in which cells fail to develop or behave normally. In that sense, a gene studied through the stripes of a small fish may illuminate fundamental principles of cell biology that extend well beyond pigmentation.

The project also carried an educational dimension that its authors regard as integral to the work. Co-authors J. Rionach McCarthy and Samuel Vernon were undergraduates when they conducted their experiments, continuing a tradition in Cooper’s laboratory that has helped prepare roughly sixty students for careers in medicine, pharmacy and research. The combination of a clinically motivated question, a transparent and tractable model organism, and hands-on training for early-career scientists reflects a model of research in which discovery and mentorship advance together.

For now, the immediate question driving the laboratory forward is mechanistic. “We’re just trying to figure out what it is about this gene that is causing changes to the activation of genes in neighboring cells,” Cooper said. “That’s what we’re up to next.” Answering that question, whether OCA2 acts through melanin-dependent signaling, through some independent function of its protein, or through indirect effects on cell interactions within the developing tissue, will determine how the zebrafish findings map onto human biology. What the study already establishes is that a gene long defined by the color it fails to produce is entangled in a much larger web of developmental control, one whose threads may run all the way to the visual difficulties experienced by people with albinism around the world.

Subject of Research: The role of the OCA2 albinism gene in pigment cell differentiation and eye development using a zebrafish model

Article Title: Zebrafish reveal wider role for gene linked to human albinism

Article References: Zebrafish reveal wider role for gene linked to human albinism. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: zebrafish, OCA2, albinism, developmental biology, pigment cells, iridophores, eye development, transcriptomics, gene expression, melanin, retina, Washington State University

The team behind the work was led by two corresponding authors from Northwestern’s Weinberg College of Arts and Sciences and the McCormick School of Engineering: Nathan Gianneschi, the Jacob & Rosaline Cohn Professor of Chemistry and a professor of materials science and engineering and biomedical engineering, and Omar Farha, the Charles E. and Emma H. Morrison Professor of Chemistry and chair of the Department of Chemistry. Their collaboration unites two research traditions that rarely intersect so directly: Gianneschi’s long-running work on synthetic melanin-like polymers and Farha’s celebrated expertise in catalytic metal-organic frameworks, porous crystalline materials that have proven exceptionally effective at capturing and destroying chemical warfare agents. By fusing these approaches, the group produced something neither could achieve alone.

To understand why the new material matters, it helps to understand the threat. Organophosphorus compounds work by sabotaging the nervous system. When one of these chemicals breaks down in the body, it releases two products. One, dimethyl phosphate, is essentially harmless. The other, a methyl nitrophenyl compound, is far more sinister: it inhibits the enzymes in blood responsible for breaking down acetylcholine, a critical neurotransmitter. When those enzymes are blocked, acetylcholine accumulates in the nervous system, overstimulating it and preventing the brain from communicating with the rest of the body. The consequences can be paralysis and death, which is precisely why nerve agents have been weaponized and why pesticide exposure remains a serious occupational hazard for agricultural workers worldwide.

Nature, it turns out, has its own strategies for coping with such substances, and the Northwestern team looked to one of the most versatile biological materials for a template. They focused on allomelanin, a renewable and biodegradable pigment that deepens the color of plants and fungi. Unlike the melanin in human skin, allomelanin is naturally porous, riddled with a network of tiny micropores that can grab and capture small harmful molecules. That intrinsic microporosity, the researchers emphasize, is not a luxury but a requirement. Sofia Aman, a graduate student in Gianneschi’s laboratory and the study’s co-first author, noted that when the team tested other melanin-like materials lacking this porosity, they did not perform as well, making allomelanin a uniquely effective substrate for the task.

Porous absorption alone, however, only traps a toxin; it does not destroy it. The second act of the design comes from chemistry. The researchers decorated their synthetic allomelanin nanoparticles with a zirconium cluster, a metal-based unit capable of catalyzing chemical reactions. Working in concert, the two components form a division of labor: the allomelanin sponge soaks up organophosphorus molecules from the surroundings, while the zirconium catalyst dismantles them. Crucially, the system shows selectivity. The allomelanin grabbed hold of the toxic chemical and broke it down while leaving the nontoxic dimethyl phosphate untouched, reducing both the quantity of the dangerous substance and its potency.

One of the most elegant engineering choices in the study addresses a practical constraint. For the catalytic reaction to proceed, the environment must be entirely basic, reaching a pH of 10 or higher. Rather than requiring users to apply an external basic compound, an impractical step in a field setting, the researchers built basic chemical groups directly onto the surface of the nanoparticles. Water then serves as the activation trigger: when the particles are wetted, the built-in basic groups create the conditions needed for the zirconium catalyst to break down the harmful chemicals. This means that in an emergency, a person exposed to a toxic organophosphorus compound could theoretically spray their clothing with water mixed with the compound, deactivating the chemical before its damaging effects take hold.

The applications extend well beyond emergency response. Because the team has previously demonstrated that their bioinspired melanins can be used to dye synthetic fabrics, the nanoparticles could be incorporated during the textile dying process itself. Gianneschi described the materials as non-toxic and suitable as an additive in clothing, facemasks, and beyond, envisioning protective clothing or breathing equipment for workers who manufacture or handle these hazardous chemicals. The populations who stand to benefit most are those with daily, unavoidable exposure: farmers who wear masks and gloves while applying pesticides, and soldiers whose uniforms and tactical gear could gain a passive layer of chemical defense woven directly into the fibers.

The material even harvests energy from its environment to work faster. Melanin reacts with sunlight and absorbs heat, and the researchers found that exposing the allomelanin to sunlight accelerates the detoxification process. In practical terms, a treated garment worn outdoors would not merely sit idle after absorbing a toxin; it would actively speed up its own decontamination under ordinary daylight. Within ten minutes, the toxic byproduct in the study decreased by fifty percent, and the reduction continued to deepen with more melanin and with sun exposure, a self-reinforcing performance profile that few synthetic protective materials can match.

Farha framed the advance as a transfer of hard-won knowledge from one class of materials to another. His group previously developed catalytic metal-organic frameworks, which he described as exceptionally powerful in the absorption and processing of chemical warfare agents. The new work takes those learnings and advances them toward melanin-inspired materials that are inherently adhesive and act as dyes for various fibers and fabrics. Melanin, he noted, is nature’s pigment as well as an efficient absorbent of small molecules and heavy metal ions in biological organisms, and the study couples those natural functions with catalysis through a combination of synthetic inorganic chemistry and biomimetic polymer science.

For Gianneschi, who has studied melanin for more than twelve years in an effort to understand its myriad functions in nature and to engineer mimetic materials for scalable, translational applications, the study represents a proof of concept for a new direction in how scientists think about protective materials and coatings design. He characterized the accumulated knowledge as a treasure trove of approaches and materials to optimize for applications like this one. The research, titled Catalytic Porous Metallized Melanin for the Remediation of Organophosphorus Agents, was supported by the Air Force Office of Scientific Research, the Army Synthetic Biology Centre for Predictive Materials Design, and the Catalyst Design for Decarbonization Center. If the concept matures from laboratory demonstration to manufactured product, the humble pigment that darkens fungi could become an invisible guardian stitched into the clothing of the people who face these poisons every day.

Subject of Research: Catalytic porous metallized melanin nanoparticles for detoxifying organophosphorus nerve agents and pesticides in protective fabrics

Article Title: Wearable nanotech could combat nerve agents

Article References: Wearable nanotech could combat nerve agents. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nanoparticles, melanin, allomelanin, nerve agents, organophosphorus, pesticides, protective clothing, zirconium catalyst, Northwestern University, ACS Nano, biomimetic materials, detoxification

The team, led by Yuan-Qing Luo of Henan University of Technology and colleagues, started from a well-known chemical paradox. Cold-pressed sesame oil retains abundant lignans, principally sesamin and sesamolin, which lend the oil oxidative stability on the shelf but carry no free phenolic hydroxyl groups and therefore little intrinsic antioxidant or anti-tyrosinase power. Roasting generates the potent antioxidant sesamol by degrading sesamolin, but it also produces an intense aroma that is unwelcome in cosmetic formulations, and industrial refining strips out sesamol and tocopherols altogether. The researchers’ solution was a solid acid-catalyzed in situ conversion, using an oxalic acid-modified mesoporous molecular sieve catalyst added directly to cold-pressed oil at 80 degrees Celsius, selectively converting the endogenous lignans into more active derivatives without creating off-flavors.

By tuning the reaction time, the team produced two bespoke oils. A short 20-minute catalytic treatment yielded a sesamol-rich oil containing 132.25 milligrams of sesamol per 100 grams, while a longer 180-minute treatment produced an asarinin-rich oil with 356.77 milligrams of asarinin per 100 grams. Untreated cold-pressed oil contained neither compound, only its native sesamin and sesamolin. Crucially, gas chromatographic analysis showed that the fatty acid backbone of the oil was essentially untouched: oleic acid and linoleic acid remained at roughly 40 and 44 percent of total fatty acids in all three samples, preserving the emollient and barrier-repair properties that make the oil matrix valuable in cosmetics. Some loss of gamma-tocopherol and phytosterols occurred, apparently through non-selective adsorption onto the mesoporous catalyst, but this was similar in both treated oils.

The first functional test targeted tyrosinase, the copper-containing enzyme that catalyzes the rate-limiting steps of melanin synthesis and stands as the principal drug target for skin-lightening agents. At 1000 micrograms per milliliter, the sesamol-rich oil inhibited tyrosinase by 91.0 percent, statistically indistinguishable from the pharmaceutical benchmark kojic acid at one-tenth the concentration. The untreated oil managed only 2.1 percent inhibition, and the asarinin-rich oil an intermediate 49.3 percent. The pattern pointed squarely at sesamol as the active principle, consistent with earlier work showing sesamol is a potent monophenolase inhibitor with an IC50 of 3.2 micromolar, far exceeding kojic acid’s 59.72 micromolar, while sesamin and sesamolin lack inhibitory activity against the enzyme.

Molecular docking offered a structural explanation. Using a predicted structure of human tyrosinase, the researchers found that sesamol binds in the hydrophobic catalytic cavity with a favorable energy of minus 5.9 kilocalories per mole, close to arbutin’s minus 6.2. More tellingly, sesamol’s phenolic hydroxyl formed a hydrogen bond with Ser375, and its aromatic ring engaged in pi-stacking with His367, while making additional contacts with His180, His202, and His363. Those histidines are not incidental: they coordinate the binuclear copper center that drives tyrosinase’s catalytic chemistry. Sesamol thus appears to jam the enzyme by perturbing the microenvironment of its dicopper active site, occupying a different subsite from arbutin and raising the possibility of cooperative binding between the two inhibitors.

To test whether the effect survives in a living organism, the team turned to zebrafish embryos, a favorite screening platform for anti-melanogenesis compounds because their optical transparency allows pigment deposition to be watched in real time and their melanin synthesis pathways closely mirror those of humans. After establishing a maximum tolerated concentration of 1 milligram per milliliter, the researchers treated embryos for 45 hours. The sesamol-rich oil reduced cephalic melanin signal by 39.04 percent, approaching the 49.34 percent achieved by the positive control arbutin at five times the concentration. Biochemical assays confirmed the mechanism: melanin protein content fell to 60.35 percent of control levels and tyrosinase activity to 64.55 percent, closely matching the visible depigmentation.

The wound-repair experiments revealed a different division of labor. In a zebrafish skin injury model created by injecting acetic acid into larvae, all three oils accelerated healing, with efficacies of 56 percent for the untreated and sesamol-rich oils and 63 percent for the asarinin-rich oil at 100 milligrams per milliliter, approaching the 69 percent of epidermal growth factor. In a tail fin amputation model, however, the asarinin-rich oil pulled decisively ahead: at 25 milligrams per milliliter it achieved 39 percent tissue regeneration, roughly 44 percent better than the sesamol-rich oil and 56 percent better than untreated oil, nearing the performance of the positive control glycoin.

Anti-inflammatory activity told the opposite story. Using transgenic zebrafish whose neutrophils glow green, the researchers tracked the resolution of inflammation at amputated tail fins, where lingering neutrophils can release toxic granules that damage tissue. At low doses of 5 and 10 milligrams per milliliter, the sesamol-rich oil cleared 56 to 57 percent of wound-site neutrophils, dramatically outperforming both the untreated oil at 34 to 36 percent and the asarinin-rich oil at 37 to 38 percent, and beating the positive control dipotassium glycyrrhizinate’s 39 percent. At 25 milligrams per milliliter the asarinin-rich oil caught up, reaching 66 percent clearance. The authors attribute these divergent profiles to the lignan chemistry: sesamol is a known suppressor of reactive oxygen species and of pro-inflammatory cytokines such as IL-1 beta, IL-6, and TNF-alpha, while asarinin has been reported to inhibit superoxide-driven inflammatory activation more potently than sesamin.

The study’s broader significance lies in its demonstration that processing chemistry, not just the source plant, determines what a functional oil can do. Because the fatty acid matrix stayed constant while lignan composition was deliberately reshaped, the researchers could attribute specific bioactivities to specific lignan enrichments, effectively converting a traditional edible oil into a tunable platform for dermocosmetic design. The authors caution that the differential effects cannot yet be pinned on single compounds, since each oil retains a mixture of lignans and minor constituents, and the lipid matrix itself may influence lignan delivery and bioavailability. They also note that the sesamol-rich oil’s UV absorption at 287 nanometers was 14.4 percent higher than untreated oil, hinting at modest photoprotective value that requires verification in finished formulations. Still, with kojic acid associated with contact dermatitis and sensitization in some users, an edible-oil-derived alternative that approaches its tyrosinase-blocking potency while simultaneously offering wound-repair and anti-inflammatory benefits represents an appealing prospect for the next generation of natural skincare ingredients.

Subject of Research: Lignan-enriched sesame oils for skin lightening and wound repair

Article Title: Exploring the Potential of Sesamol/Asarinin-Enriched Sesame Oil in Skin Lightening and Wound Repair

Article References: Luo, Y.-Q., Li, Z.-Q., Wang, Q., Qin, J.-W., Yu, T., Liu, H.-M., & Yang, J.-C. (2026). Exploring the Potential of Sesamol/Asarinin-Enriched Sesame Oil in Skin Lightening and Wound Repair. Journal of Agriculture and Food Research, Article 103348. https://doi.org/10.1016/j.jafr.2026.103348

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103348

Keywords: sesame oil, sesamol, asarinin, tyrosinase, melanin, skin lightening, wound healing, zebrafish, lignans, cosmetics, anti-inflammatory, molecular docking

The trouble with conventional tools is well documented. Two-dimensional cell cultures, such as the widely used B16F10 mouse melanoma line, are accessible and highly pigmented but do not capture the molecular heterogeneity of human disease. Human melanoma lines like the Sk-Mel series, MNT-1, and A375 offer more relevant genetics but remain simplified. Primary melanocytes isolated from skin biopsies behave more like cells in the body but survive only a limited number of passages before senescence. Animal models—mice, zebrafish, the frog Xenopus laevis, guinea pigs, swine, chick embryos, and fruit flies—each bring valuable features, from the optical clarity of zebrafish embryos to the tyrosinase-dependent, MITF-independent melanin deposition in Xenopus, but they suffer from divergent protein–protein interactions, species-specific genetics, high costs, and mounting ethical constraints. Most critically, identical visible pigmentation phenotypes in humans can arise from entirely distinct molecular disruptions, a depth of heterogeneity that flat cultures and cross-species models frequently miss, leading to inconsistent and unpredictable therapeutic responses.

The review, published in Bioengineering & Translational Medicine, organizes the emerging alternative into three converging categories unified by the iterative Design-Build-Test-Learn engineering cycle. The first is classical synthetic biology: direct genetic and metabolic rewiring using tools such as CRISPR-Cas9, TALENs, and heterologous microbial expression. CRISPR-Cas9, adapted from a bacterial immune system, uses a guide RNA to direct the Cas9 endonuclease to a precise DNA target, where the resulting break is repaired by non-homologous end joining or homology-directed repair. Researchers have exploited this to build exquisitely controlled disease models: knocking out SIRT1 in murine melanoma cells suppresses melanogenesis by reducing MITF expression through altered p38 and ERK signaling, creating a hypopigmentation model relevant to vitiligo, whereas ablating SIRT7 upregulates melanin production via MITF and its downstream enzymes, mimicking melasma and lentigines. In a striking proof of concept, CRISPR was used to correct the T373K missense mutation that abolishes tyrosinase activity in oculocutaneous albinism, restoring enzyme function and melanin content in an animal model and establishing a precise genotype-to-phenotype platform with implications for somatic gene therapy.

Delivery remains the central obstacle to translating these edits into clinic-ready treatments, because the stratum corneum aggressively blocks large molecular cargos and viral vectors carry limited capacity and immunogenic risks. Recent bioengineering work points toward non-viral solutions. A polyamine-modified thermosensitive hydrogel, liquid at refrigerator temperature but gelling at body temperature, has successfully delivered CRISPR-Cas9 ribonucleoproteins through the skin, achieving a 46 percent gene mutation frequency in vivo with no systemic toxicity. Complementary ex vivo strategies—correcting a patient’s own skin cells in the laboratory, expanding them as epidermal sheets, and grafting them back—offer a path to durable, safety-validated gene correction for genetic skin disorders. TALENs, which pair a DNA-binding domain with a FokI nuclease, add a second editing option with lower off-target risk, as demonstrated by disrupting the slc24a5 gene in tuna to produce hypopigmentation.

The second category, heterologous expression systems, swaps slow mammalian kinetics for engineered microbes, transforming melanin from a scarce biological product into an industrially manufacturable biomaterial. The standout example is the marine bacterium Vibrio natriegens, which doubles roughly every ten minutes; when engineered to express a prokaryotic tyrosinase from Bacillus megaterium and supplemented with L-tyrosine and copper, it generates visible melanin within fifteen minutes and saturates the culture within two hours. The same platform demonstrated optogenetic control, using blue light to derepress tyrosinase expression with reversible, spatially precise timing. Parallel efforts in Escherichia coli express tyrosinases such as melA from Rhizobium etli or route flux through the hppd gene to produce pyomelanin, while modular co-expression of multiple enzymes yields non-natural variants like melanin-diamine complexes optimized for fabric dyeing. Eukaryotic hosts fill the gap where post-translational modification matters: the yeast Yarrowia lipolytica secretes pyomelanin with photoprotective and antioxidant properties suitable for dermatological formulations, retaining the glycosylation machinery that bacteria lack.

The third and physiologically richest category comprises biomimetic systems that recreate the dynamic microenvironment of living skin. Co-culturing primary melanocytes and keratinocytes from vitiligo patients produces a patient-specific platform whose drug responses differ markedly from healthy controls—resistant to melanogenic stimulators and hypersensitive to inhibitors—making it a predictive preclinical proxy. Three-dimensional melanocyte spheroids rescue the melanin production that flat monolayers lose, and when treated with the skin-lightening compound fucoxanthin they outperform commercial tissue equivalents in sensitivity. Perhaps most impressive are microfluidic skin-on-a-chip devices: one bilayer-hydrogel platform, perfused with circulating 17β-estradiol and tuned oxygen gradients, reproduces the exact hyperpigmentation patterns of pregnancy-induced melasma, demonstrating that hormone-driven disorders can now be modeled outside the body. Skin explants preserved in gravity-driven, pumpless chips maintain viability for clinical monitoring and personalized testing.

At the macroscopic end of the spectrum, 3D bioprinting and reconstructed human pigmented skin (RHPS) and epidermis (RHPE) models bring structural fidelity to high-throughput screening. Printed bioinks containing live cells and gelatin-alginate matrices are cross-linked, cultured submerged, and then shifted to an air-liquid interface, where exposure to air forces keratinocytes to differentiate and stratify into a viable, keratinized epidermis. Commercial systems such as MelanoDerm, EpiSkin, SkinEthic, and EpiDerm, built from melanocytes and keratinocytes of diverse genetic ancestries, already support safety testing accepted by regulators for dermal irritation and phototoxicity under New Approach Methodologies aligned with the 3Rs of animal research. Pushing to the sub-cellular scale, researchers have engineered artificial melanosomes—tyrosinase encapsulated in lipid vesicles or polymersomes—that synthesize melanin only when triggered by ultraviolet light or that migrate to the perinuclear region of keratinocytes, mimicking the DNA-shielding nuclear caps of native melanosomes. Stem cell technologies extend the vision toward regenerative medicine, with induced pluripotent stem cell–derived melanocytes and MUSE cells integrating into the basal layer of skin organoids without tumorigenic risk.

Complementing all of these live systems are cell-free assays that strip melanogenesis down to its isolated biochemistry. Simple tyrosinase assays using L-DOPA remain a gold standard for rapid inhibitor screening, and they delivered a definitive mechanistic answer in the case of plumbagin, confirming it as a direct enzymatic inhibitor rather than an upstream regulator. More advanced transcription-translation (TXTL) systems can synthesize melanogenic proteins entirely outside living cells, sidestepping host toxicity and metabolic competition. These reductionist platforms are exceptionally reproducible but deliberately blind to membrane permeability and cellular feedback loops, so their findings must be validated in more complex biomimetic models. Emerging cell-free regenerative approaches—platelet-rich plasma, extracellular vesicles, and stem cell secretomes—may bypass transplantation risks altogether by stimulating resident melanocyte precursors and countering oxidative stress in disorders such as vitiligo.

The review is candid about remaining gaps. Engineered microbes are scalable but poorly represent human melanocyte biology; biomimetic constructs are physiologically faithful but expensive, hard to standardize, and still lack immune, vascular, and neural components. CRISPR faces off-target effects, immune recognition of bacterial Cas9, and delivery challenges in continuously renewing skin, prompting development of high-fidelity variants and anti-CRISPR safeguards. Engineered live therapeutics fall under strict regulatory oversight, and industrial melanin production demands biosafety containment and genetic safeguards against environmental release. Yet the trajectory is clear: by unifying programmable gene circuits, engineered microbes, printed tissue, organ-on-chip microenvironments, and synthetic organelles under shared engineering principles, researchers are replacing unpredictable and ethically constrained models with controllable biosystems. The payoff spans next-generation diagnostics, targeted therapies for vitiligo and melasma, biologically integrated sunscreens, antioxidant delivery vehicles, melanin-based radiometal sorbents for nuclear medicine, and even organic semiconductors—a breadth that positions engineered pigmentation platforms as one of the most versatile toolkits in modern dermatology.

Subject of Research: Engineered synthetic biology and biomimetic platforms for studying melanogenesis and pigmentation disorders

Article Title: Engineered platforms for melanogenesis research: Bridging synthetic biology, bioengineering, and biomimetics

Article References: Anika, B., Tarkunde, A., Swarna, B. S., Nayak, U. Y., Prabhu, V., Rao, R., & Bharath Prasad, A. S. (2026). Engineered platforms for melanogenesis research: Bridging synthetic biology, bioengineering, and biomimetics. Bioengineering & Translational Medicine, 11(5), Article e70159. https://doi.org/10.1002/btm2.70159

Image Credits: AI Generated

DOI: 10.1002/btm2.70159

Keywords: melanogenesis, melanin, synthetic biology, CRISPR-Cas9, biomimetics, 3D bioprinting, skin-on-a-chip, artificial melanosomes, heterologous expression, vitiligo, melasma, reconstructed human skin